

DAFTAR PUSTAKA

1. Markum HMS. Gangguan ginjal akut. Dalam Buku Ajar Ilmu Penyakit Dalam Edisi 6. Sudoyo A, Setiyohadi B, Alwi I, Simadibrata K, Setiati S, editors. Jakarta: InternaPublishing; 2014: 2166–75
2. Adiyanti SS, Loho T. Acute kidney injury (AKI) biomarker. *Acta Med Indones Journal Intern Med.* 2012; 44: 246–55
3. Rao S, Jim B. Acute kidney injury in pregnancy : The changing landscape for the 21st century. *Kidney International Reports.* 2018: 1–11
4. Callaghan W, Creanga A, Kuklina E. Severe maternal morbidity among delivery and postpartum hospitaliations in the United States. *Obstet Gynecol.* 2012; 120: 1029–36
5. Yang L. Acute kidney injury in Asia. *Kidney Dis.* 2016; 2: 95–102
6. Bouchard J, Mehta LL. Acute kidney injury in western countries. *Kidney Dis.* 2016; 2: 103–10
7. Liu YM, Jiang ZZ, Huang YJ, Wang NS. Pregnancy-related acute kidney injury and a review of the literature in China. *Internal Medicine.* 2015; 54: 1695–703
8. Prakash J, Ganiger V, Prakash S, Iqbal M, Kar D, Singh U, et al. Acute kidney injury in pregnancy with special reference to pregnancy-specific disorders: a hospital based study (2014-2016). *Journal of Nephrology.* 2018: 1–7
9. Lambert G, Brichant J, Hartstein G, Bonhomme V, Dewandre P. Preeclampsia : an update. *Acta Anaesth Belg.* 2014; 65: 137–49
10. Hutcheon JA, Lisonkova S, Joseph K. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. *Best Practice & Research Clinical Obstetrics and Gynaecology.* 2011; 25: 391–403
11. Osungbade KO, Ige OK. Public health perspectives of preeclampsia in developing countries: Implication for health system strengthening. *Journal of*

- Pregnancy. 2011: 1–6
12. Prakash J, Vohra R, Pandey L, Niwas S, Behura S, Singh U. Spectrum of kidney diseases in patients with preeclampsia-eclampsia. *JAPI*. 2010; 58: 543–6
 13. Shiozaki A, Matsuda Y, Satoh S, Saito S. Impact of fetal sex in pregnancy-induced hypertension in Japan. *J Reprod Immunol*. 2011; 89: 133–9
 14. Handayani RR, Adisasmita AC. Kejadian komplikasi maternal: Pelaporan di rumah sakit dan hasil riskesdas di Indonesia tahun 2010 (Analisis SIRS dan RISKESDAS). [Online].; 2013. Available from: <http://www.lib.ui.ac.id>
 15. Pratama D. Korelasi kadar sFlt-1 serum dengan tekanan darah pada preeklamsia berat. e-Skripsi Universitas Andalas. 2016: 1–73
 16. Yudianto , Budijanto D, Hardhana B, Soenardi T. Profil kesehatan Indonesia 2014. Kementerian Kesehatan RI. 2015: 1–187
 17. Huang C, Chen S. Acute kidney injury during pregnancy and puerperium : a retrospective study in a single center. *BMC Nephrology*. 2017; 18(146): 1–9
 18. Prakash J, Niwas SS, Parekh A, Pandey LK, Sharatchandra L, Arora P, et al. Acute kidney injury in late pregnancy in developing countries. *Renal Failure*. 2010; 32: 309–13
 19. Hildebrand A. Electronic Thesis and Dissertation Repository. [Online].; 2017. Available from: <https://ir.lib.uwo.ca/etd>
 20. McDonald SD, Han Z, Walsh MW, Gerstein HC, Devereaux PJ. Kidney disease after preeclampsia: A systemic review and meta-analysis. *American Journal of Kidney Diseases*. 2010; 55(6): 1026–39
 21. Shahbazian N, Shahbazian H, Ehsanpour A, Aref A, Gharibzadeh S. Hypertension and microalbuminuria 5 years after pregnancies complicated by pre-eclampsia. *Iranian Journal of Kidney Disease*. 2011; 5(6): 324–7
 22. Julia S, van Balen V, Peeters L, Spaanderman M. Prevalence of chronic kidney disease after preeclampsia using KDIGO 2012 criteria. *Pregnancy hypertension : An international journal of women's cardiovascular health* 5. 2015; 2(52): 35–6

23. van Balen V, Spaan J, Cornelis T, Spaanderman M. Prevalence of chronic kidney disease after preeclampsia. *J Nephrol*. 2017; 30: 403–9
24. Toering TJ, van der Graaf AM, Faas MM, Lely AT. From preeclampsia to renal disease : a role of angiogenic factors and the renin-angiotensin aldosterone system? *Nephrol Dial Transplant*. 2012; 27(3): 40–55
25. Aggarwal PK, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. *Journal of Human Hypertension*. 2012; 26: 236–41
26. Cerderia AS, Karumanchi SA. Angiogenic factors in preeclampsia and related disorder. *Cold Spring Harb Perspect Med*. 2012; 2: 1–18
27. Jung J, Tiwari A, Inamdar SM, Thomas C, Goel A, Choudhury A. Secretion of soluble vascular endothelial growth factor receptor 1 (sVEGFR1/sFlt1) requires Arf 1, Arf6 and Rab 11 GTPases. *Plos One*. 2012; 7(9): 1–11
28. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. *The journal of biological chemistry*. 2003; 278: 12605–8
29. Maynard S, Min J, Merchan J, Lim K, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *The Journal of Clinical Investigation*. 2003; 111(5): 649–58
30. Jiang Z, Zou Y, Ge Z, Zuo Q, Huan SY, Sun L. A role of sFlt-1 in oxidative stress and apoptosis in human and mouse pre-eclamptic trophoblasts. *Biology of reproduction*. 2015; 93(4): 1–7
31. Levine R, Maynard S, Qian C, Lim K, England L. Circulating angiogenic factors and the risk of preeclampsia. *The New England Journal of Medicine*. 2004: 1076–85
32. Yoshimatsu J, Matsumoto H, Goto K, Shimano M, Narahara H, Miyakawa I. Relationship between urinary albumin and serum soluble fms-like tyrosine kinase 1 (sFlt-1) in normal pregnancy. *European Journal of Obstetrics &*

- Gynecology and Reproductive Biology. 2006; 128: 204–8
33. Ramma W, Buhimschi I, Zhao G, Dulay A, Nayeri U, Buhimschi C. The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia. *Angiogenesis*. 2012; 15: 333–40
 34. Kaleta T, Stock A, Panayotopoulos D, Vonend O, Niederacher D, Neumann M, et al. Predictors of impaired postpartum renal function in women after preeclampsia: results of a prospective single center study. *Disease Markers*. 2016: 1–8
 35. Saputro PE, Ermawati, Machmud R. Perbedaan rasio serum soluble fms-like tyrosine kinase-1 (sFlt-1) dan placental growth factor (PlGF) antara kehamilan normal dan kehamilan preeklamsia berat pada usia kehamilan 24-34 minggu. *e-Skripsi Universitas Andalas*. 2016: 1–68
 36. Rahmi L, Herman RB, Yusrawati. Perbedaan rerata kadar soluble fms-like tyrosine kinase-1 (sFlt-1) serum dengan penderita early onset, late onset preeklamsia berat/eklamsia dan kehamilan normal. *Jurnal Kesehatan Andalas*. 2016; 5(1): 41–8
 37. Stillman I, Karumanchi S. The glomerular injury of preeclampsia. *J Am Soc Nephrol*. 2007; 18: 2281–4
 38. Sulistyowati S, Irawan D, Edwin E, Soetrisno. VEGF 121 rekombinan dapat memperbaiki endoteliosis glomerular pada mencit bunting modek preeklamsia. *Obstetri & Ginekologi*. 2016; 24(1): 19-24
 39. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. In *Kidney International Supplements*; 2012: 1–138
 40. Siribamrungwong M, Chinudomwong P. Relation between acute kidney injury and pregnancy-related factors. *Journal of acute disease*. 2016; 5(1): 22–8
 41. Roesli RMA. *Diagnosis dan Pengelolaan gangguan ginjal akut*. Edisi Ke-2. Jakarta; 2011: 1–30
 42. Prakash J, Ganiger V. Acute kidney injury in pregnancy-specific disorders. *Indian J Nephrol*. 2017; 27: 258–70

43. Najjar M, Shah A, Wani I, Reshi A, Banday K, Bhat Mea. Pregnancy related acute kidney injury: a single center experience from the Kashmir Valley. *Indian J Nephrol.* 2008; 18: 159–61
44. Nwoko R, Plecas D, Garovic V. Acute kidney injury in the pregnant patient. *Clin Nephrol.* 2012; 78(6): 478–86
45. Gorsane I, Mahfoudhi M, Euch M, Abdallah T. Acute kidney injury in pregnancy : a single center study in Tunisia. *Int J of Clin Med.* 2015; 6: 729–33
46. Eswarappa M, Madhyastha P, Puri S, Varma V, Bhandari A, Chennabassappa G. Postpartum acute kidney injury: a review of 99 cases. *Renal Failure.* 2016: 1–5
47. Acharya A, Santos J, Linde B, Anis K. Acute kidney injury in pregnancy-current status. *Advances in Chronic Kidney Disease.* 2013; 20(3): 215–22
48. Task Force on Hypertension in Pregnancy. Hypertension in pregnancy Washington DC: American College of Obstetricians and Gynecologists; 2013: 1–89
49. McCarthy FP, Kenny LC. Classification and diagnosis of hypertension in pregnancy. In Heazell A, Norwitz ER, Kenny LC, Baker PN, editors. *Hypertension in Pregnancy.* USA: Cambridge University Press; 2010: 35–44
50. Cunningham F. Hypertensive disorders in pregnancy. In *Williams Obstetrics*, 24th eds. New York: The McGraw-Hill Companies; 2014. 1515–6
51. Mustafa R, Ahmed S, Gupta A, Venuto RC. A comprehensive review of hypertension in pregnancy. *Journal of Pregnancy.* 2012: 1–20
52. Powe C, Levine R, Karumanchi A. Preeclampsia , a disease of the maternal endothelium : the role of anti-angiogenic factors and implications for later cardiovascular disease. *Circulation.* 2011; 123(24): 1–27
53. Redman C, Sargent I. The pathogenesis of pre-eclampsia. *Gynecol Obstet Fertil.* 2001; 29: 518–22
54. Kumar P, Sharma JB. Hypertensive disorders in pregnancy. *JIMSA.* 2010:.

261–6

55. Subandrate , Faisal ME, Anggraini NW. Peranan stres oksidatif pada preeklampsia. *CDK-252*. 2017; 44(5): 353–5
56. Nilsson E, Ros H, Crattingius Sea. The importance of genetic and environmental effects for preeclampsia and gestational hypertension: A family study. *Brithis Journal Obstetrics and Gynaecology*. 2004; 111: 200–6
57. Ward K, Taylor R. Genetic factors in the etiology of preeclampsia. In Taylor R, Roberts J, Cunningham F. *Chesley's hypertensive disorders in pregnancy*, 4th ed. Amsterdam: Academic Press; 2014. 1–292
58. FG C, Roberts J, Taylor R. The clinical spectrum of preeclampsia. In Taylor R, Roberts J, Cunningham F, Lindheimer M, editors. *Chesley's hypertensive disorders in pregnancy*. 4th ed. Amsterdam: Elsevier; 2015: 25–34
59. Possomato-Vieira J, Khalil R. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. *Advances in Pharmacology*. 2016; 77(11): 361–431
60. Haggmann H, Bosung V, Belaidi A, Fridman A, Karumanchi S, Thadhani R. Low molecular weight heparin increase circulating sFlt-1 levels and enhances urinary elimination. *Plos One*. 2014; 9(1): 1–8
61. Taylor R, Cunningham F. *Chesley's hypertensive disorder in pregnancy*, 4th ed London: Elsevier Inc; 2015: 1–484
62. Schoofs K, Grittner U, Engels T, Pape J, Denk B. The importance of repeated measeruments of the sFlt-1/PIGF ratio for the prediction of preeclampsia and intrauterine growth restriction. *Jornal of perinatology medicine*. 2014; 42(1): 61–8
63. Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in the diagnosis and prediction of preeclampsia. *Clin Sci*. 2012; 2: 43–52
64. Davidson J, Homuth V, Jeyabalan A, Conrad K, Karumanchi A, Quaggin S. New aspects in the pathophysiology of preeclampsia. *J Am Soc Nephrol*. 2004: 2440–8
65. Arriaga P, Herraiz I, Jimene E, Montes E, Denk B, Galindo A. Uterine artery

- doppler and sFlt-1/PIGF ratio : usefulness in diagnosis of preeclampsia. *Ultrasound Obstetry Gynecology*. 2013; 41: 530–7
66. McKeeman, Ardill, Caldwell, Hunter, McClure. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased through gestation in patients who have preeclampsia develop. *American Journal of Obstetrics & Gynecology*. 2010: 1240–6
67. Olav L, Andrew S, Holger S. The preeclampsia biomarkers soluble fms like tyrosine kinase-1 and placental growth factor : current knowledge, clinical implications and future application. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2010: 122–9
68. Ohkuchi A, Hirashima C, Takahashi K, Suzuki H, Matsubara S, Suzuki M. Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation. *Hypertension Research*. 2013; 36: 1073–80
69. March M, Geahchan C, Wenger J, Raghuraman N, Berg A, Haddow H, et al. Circulating angiogenic factors and the risk of adverse outcomes among Haitian women with preeclampsia. *PLoS One*. 2015; 10: 1–12
70. Bian Z, Shixia C, Duan T. First-trimester maternal serum levels of sFlt1, PGF and ADMA predict preeclampsia. *Plos One*. 2015: 1–12
71. Meng W, Zhanashunbayaer , E L, Li R. Association between asymmetric dimethylarginine level and preeclampsia : a meta analysis. *Int J Clin Exp Med*. 2017; 10(6): 8720–7
72. Groesch K, Torry R, Wilber A, Abrams R, Bieniarz A, Guilbert L, et al. Nitric oxide generation affects pro-and anti-angiogenic growth factor expression in primary human trophoblast. *Placenta*. 2011; 32: 926–31
73. Li F, Hagaman J, Kim H, Maeda N, Jennette J, Faber J, et al. eNOS deficiency acts through endothelin to aggravate sFlt1-induced pre-eclampsia-like phenotype. *J Am Soc Nephrol*. 2012; 23: 652–60
74. Murphy S, LaMarca B, Parrish M, Cockrell K, Granger J. Control of soluble

- fms-like tyrosine-1 (sFlt-1) production response to placental ischaemia/hypoxia: role of tumor necrosis factor alpha. *AJP-Regul Integr Comp Physiol*. 2013; 304: R130–5
75. Appel S, Turnwald E, Ankerne J, Wohlfarth M, Appel J, Rother E, et al. Hypoxia-mediated soluble fms-tyrosine kinase 1 increase is not attenuated in interleukin 6-deficient mice. *Reproductive Sciences*. 2014: 1–8
76. Udenze I, Amadi C, Awolola N, Makwe C. The role of cytokines as inflammatory mediators in preeclampsia. *Pan Africa Medical Journal*. 2015; 20(219): 1–6
77. Gennari-Moser C, Khankin EV, Escher G, Burkhard F, Frey BM, Karumanchi S, et al. Vascular endothelial growth factor-A and aldosterone relevance to normal pregnancy and preeclampsia. *Hypertension*. 2013: 1111–7
78. Rolfo A, Attini R, Tavassoli E, Neve F, Nigra M, Cicilano M. Is it possible to differentiate chronic kidney disease and preeclampsia by means of new and old biomarkers? A prospective study. Hindawi Publishing Corporation. 2015; 2015: 1–8
79. Kabbali N, Tachfouti N, Arrayhani M, Harandou M, Tagnaouti M, Bentata Y. Outcome assessment of pregnancy-related acute kidney injury in Morocco: A national prospective study. *Saudi J Kidney Dis Transpl*. 2015; 26(3): 619–24
80. Ramesh K, Gandhi S, Rao V. Socio-demographic and other risk actors of preeclampsia at a tertiary care hospital, Karnataka : Case control study. *Journal of Clinical and Diagnostic Research*. 2014; 8(9): JC01–4
81. Tangren J, Powe C, Ankers E, Ecker J. Pregnancy outcomes after clinical recovery from AKI. *J Am Soc Nephrol*. 2016; 28: 1–9
82. Lasiaprillianty I, Ernawati. Hubungan IL-10 dengan serum kreatinin dan terjadinya komplikasi pada preeklampsia perawatan konservatif. *Majalah Obstetri & Ginekologi*. 2015; 23(2): 82–9
83. Asmana S, Syahredi , Hilbertina N. Hubungan Usia dan Paritas dengan Kejadian Preeklampsia Berat di Rumah Sakit Achmad Mochtar Bukittinggi Tahun 2012-2013. *Jurnal Kesehatan Andalas*. 2016; 5(3): 640–6

84. Bdolah Y, Elchalah U, Natanson-Yaron S, Yechiam H, Bdolah-Abram T, Greenfield C, et al. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. *Hypertension in Pregnancy*. 2014; 33(2): 250–9
85. Fadhila I, Herman R, Yusrawati. Hubungan antara tekanan darah dan fungsi ginjal pada preeklamsi di RSUP Dr. M Djamil. *Jurnal Kesehatan Andalas*. 2018; 7(1): 59–64
86. Reddy A, Suri S, Sargent I, Redman C, Muttukhrisna S. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and preeclampsia. *PLoS ONE*. 2009; 4(2): e4453
87. Moran P. Glomerular ultrafiltration in normal and preeclamptic pregnancy. *J Am Soc Nephrol*. 2003; 14(3): p. 648–52
88. Unverdi S, Ceri M, Unverdi H, Yilmaz R, Akcay A, Duranay M. Postpartum persistent proteinuria after preeclampsia: a single-center experience. *Wiener Klinische Wochenschrift*. 2013; 125: 91–5
89. LaMarca B. Endothelial dysfunction; an important mediator in the pathophysiology of hypertension during preeclampsia. *Minerva Ginecol*. 2012; 64(4): 309–20
90. Radulescu C, Bacaarea A, Hutanu A, Gabor R, Dobreanu M. Placental growth factor, soluble fms-like tyrosine kinase I, soluble endoglin, IL-6 and IL-16 as biomarkers in preeclampsia. *Mediators of inflammation*. 2016; 2016: 1–8
91. Sanchez-Aranguen L, Prada C, Riano-Medina C, Lopez M. Endothelial dysfunction and preeclampsia; role of oxidative stress. *Frontiers in physiology*. 2014; 5: 1–11
92. Gathiram P, Moodley J. Preeclampsia: its pathogenesis and pathophysiology. *Cardiovascular Journal of Africa*. 2016; 27(2): 71–8
93. Hladunewich M, Karumanchi S, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. *Clin J Am Soc Nephrol*. 2007; 2: 543–9
94. Thomas C, Thomas L. Renal failure-measuring the glomerular filtration rate. *Dtsch Arztebl Int*. 2009; 106(51): 849–54

95. Di Marco G, Reuter S, Hillebrand U, Amler S, Konig M, Larger E. The soluble VEGF receptor sFlt-1 contributes to endothelial dysfunction in CKD. *J Am Soc Nephrology*. 2009; 20: 2235–45
96. Gurnadi J, Mose J, Handono B, Anwar A, Fauziah P, Pramatirta A. Difference of concentration of placental soluble fms like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy. *BioMed Central*. 2015; 8(534): 1–5

